🇺🇸 FDA
Pipeline program

bempegaldesleukin

17-214-09

Phase 3 mab terminated

Quick answer

bempegaldesleukin for Renal Cell Carcinoma is a Phase 3 program (mab) at NEKTAR THERAPEUTICS with 1 ClinicalTrials.gov record(s).

Program details

Company
NEKTAR THERAPEUTICS
Indication
Renal Cell Carcinoma
Phase
Phase 3
Modality
mab
Status
terminated

Clinical trials